Patents Assigned to Celera Corporation
  • Patent number: 11827937
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular disease, especially coronary heart disease (such as myocardial infarction) and stroke. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents and kits for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents and kits for their detection.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: November 28, 2023
    Assignee: Celera Corporation
    Inventor: Dov Shiffman
  • Patent number: 11814684
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with coronary heart disease (particularly myocardial infarction), aneurysm/dissection, and/or response to drug treatment, particularly statin treatment. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: November 14, 2023
    Assignee: Celera Corporation
    Inventors: Olga Iakoubova, James J. Devlin, Carmen Tong, Charles Rowland
  • Patent number: 11802164
    Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: October 31, 2023
    Assignee: Celera Corporation
    Inventors: Steve Ruben, Tao He, Candy Lee, Karen Van Orden, Paul Moore
  • Patent number: 11788143
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: October 17, 2023
    Assignee: Celera Corporation
    Inventors: Yonghong Li, Steven Schrodi, Ann Begovich, Monica Chang
  • Patent number: 11708610
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual to treatment of cardiovascular disorders with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: July 25, 2023
    Assignee: Celera Corporation
    Inventors: Olga Iakoubova, James J. Devlin, Zenta Tsuchihashi, Peter Shaw, Lynn Marie Ploughman, Kim E. Zerba, Koustubh Ranade, Todd Kirchgessner
  • Patent number: 11697850
    Abstract: This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: July 11, 2023
    Assignees: The Brigham and Women's Hospital, Inc., Celera Corporation
    Inventors: Paul M. Ridker, Daniel Chasman, Dov Shiffman
  • Patent number: 11408034
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with cardiovascular diseases, particularly coronary heart disease (especially myocardial infarction) or hypertension. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: August 9, 2022
    Assignee: Celera Corporation
    Inventors: Dov Shiffman, James J. Devlin, Judy Z. Louie, Eric Boerwinkle
  • Patent number: 11401555
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with vascular diseases such as stroke. In particular, the present invention relates to genetic polymorphisms that have utility for such uses as predicting disease risk or predicting an individual's response to a treatment such as statins, including groups of polymorphisms that may be used as a signature marker set for such uses, as well as nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: August 2, 2022
    Assignee: Celera Corporation
    Inventors: May Luke, James J. Devlin
  • Patent number: 11124834
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with venous thrombosis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: September 21, 2021
    Assignee: Celera Corporation
    Inventors: Lance Bare, James J. Devlin, Frits R. Rosendaal, Pieter H. Reitsma, Irene D. Bezemer
  • Patent number: 11105806
    Abstract: Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: August 31, 2021
    Assignee: Celera Corporation
    Inventors: Charles Birse, Steve Ruben, Marcia Lewis, Mehdi Mesri
  • Patent number: 11041209
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with myocardial infarction. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: June 22, 2021
    Assignee: Celera Corporation
    Inventors: Olga Iakoubova, James J. Devlin
  • Patent number: 11028445
    Abstract: The present invention is based on the discovery of a unique 14-gene molecular prognostic signature that is useful for predicting breast cancer metastasis. In particular, the present invention relates to methods and reagents for detecting and profiling the expression levels of these genes, and methods of using the expression level information in predicting risk of breast cancer metastasis.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: June 8, 2021
    Assignee: Celera Corporation
    Inventors: Kit Lau, Alice Wang
  • Patent number: 11008618
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with autoinflammatory diseases such as psoriasis. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: May 18, 2021
    Assignee: Celera Corporation
    Inventors: Steven Schrodi, Yonghong Li
  • Patent number: 10988809
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with coronary heart disease (particularly myocardial infarction), aneurysm/dissection, and/or response to drug treatment, particularly statin treatment. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: April 27, 2021
    Assignee: Celera Corporation
    Inventors: Olga Iakoubova, James J. Devlin, Carmen Tong, Charles Rowland
  • Patent number: 10982281
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual to treatment of cardiovascular disorders with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: April 20, 2021
    Assignee: Celera Corporation
    Inventors: Olga Iakoubova, James J. Devlin, Zenta Tsuchihashi, Peter Shaw, Lynn Marie Ploughman, Kim E. Zerba, Koustubh Ranade, Todd Kirchgessner
  • Patent number: 10954565
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: March 23, 2021
    Assignee: Celera Corporation
    Inventors: Yonghong Li, Steven Schrodi, Ann Begovich, Monica Chang
  • Patent number: 10920276
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: February 16, 2021
    Assignee: Celera Corporation
    Inventors: Ann Begovich, Ellen Beasley, Steven Schrodi
  • Publication number: 20210017259
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.
    Type: Application
    Filed: March 25, 2020
    Publication date: January 21, 2021
    Applicant: CELERA CORPORATION
    Inventors: Yeounjin KIM, Tao HE, Steve RUBEN
  • Patent number: 10718023
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: July 21, 2020
    Assignee: Celera Corporation
    Inventor: Hongjin Huang
  • Patent number: 10584384
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with cardiovascular diseases, particularly coronary heart disease (especially myocardial infarction) or hypertension. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: March 10, 2020
    Assignee: Celera Corporation
    Inventors: Dov Shiffman, James J. Devlin, Judy Z. Louie, Eric Boerwinkle